EXPLANATORY STATEMENT
STATUTORY RULES 1986 NO 112
ISSUED BY THE AUTHORITY OF THE MINISTER FOR HEALTH
COMMONWEALTH SERUM LABORATORIES ACT 1961
COMMONWEALTH SERUM LABORATORIES REGULATIONS
(AMENDMENT)
Section 45 of the Commonwealth Serum Laboratories Act 1961 (the Act) provides that the Governor-General may make regulations, not inconsistent with the Act, prescribing all matters required or permitted by the Act to be prescribed, or necessary or convenient to be prescribed, for carrying out or giving effect to the Act.
The Health Legislation Amendment Act (No 2) 1985 inserted a new sub-paragraph 19(1)(b)(iiia) into the Act to provide that where the Minister so determines, the functions of the Commonwealth Serum Laboratories Commission (the Commission) include cooperation with a Government or organisation, whether Australian, or foreign, or an international organisation, in respect of research relating to production of or prescribed operations relating to the production of pharmaceutical products.
Paragraphs 20(2)(a) and 20(2)(b) of the Act provide that the Commission shall not, without the Minister’s approval, enter into any contract for the sale or purchase of pharmaceutical goods where the contract exceeds $500,000 or for any other purpose where the contract exceeds $250,000.
The regulations prescribe for the purposes of sub-paragraph 19(1)(b)(iiia) of the Act the types of operations which the Commission may be required to undertake in accordance with a request for cooperation from a Government or organisation.
The regulations also prescribe, for the purposes of paragraphs 20(2)(a) and 20(2)(b) of the Act, amounts of $2,000,000 and $1,000,000 respectively. The existing amounts were set in 1980 and since that time the value of contracts entered into by the Commission has increased rapidly and the ceilings have been increased to more realistic levels so that the Minister’s approval is not required for routine operational matters.
The regulations also effect minor drafting changes.
The regulations came into operation on the date of their notification in the Commonwealth of Australia Gazette.
Overview
The Commonwealth Serum Laboratories Regulations (Amendment) 2004 were enacted to update the monetary thresholds for certain contractual approvals under the Commonwealth Serum Laboratories Act 1961. This Act, established to govern the operations of the Commonwealth Serum Laboratories, was initially intended to ensure the efficient and effective production of pharmaceutical products in Australia. The 1985 amendment introduced the concept of international cooperation in pharmaceutical research, necessitating updated regulatory thresholds to accommodate the changing economic landscape. The new regulations, issued under the authority of the Minister for Health, set higher ceilings for the approval of significant contracts, reflecting the increased value of transactions in the pharmaceutical industry. This amendment aimed to streamline the operational efficiency of the Commonwealth Serum Laboratories Commission by reducing the need for ministerial approval on routine matters, thereby facilitating more agile decision-making processes. The updated thresholds of $2,000,000 and $1,000,000 for pharmaceutical sales and other contracts, respectively, were designed to be more reflective of contemporary economic conditions and to ensure the Commission could operate effectively within its regulatory framework.
Scope and Application
The Commonwealth Serum Laboratories Regulations (Amendment) Statutory Rules 1986, issued under the authority of the Minister for Health, amend the Commonwealth Serum Laboratories Regulations to update the monetary thresholds for contracts that require ministerial approval. The Act applies to the Commonwealth Serum Laboratories Commission, which is responsible for carrying out functions related to the production of pharmaceutical products, including research and cooperation with foreign and international entities. The amendments ensure that the thresholds for requiring ministerial approval for contracts are adjusted to reflect the increased value of contracts entered into by the Commission, thereby allowing for more efficient routine operations. The updated thresholds set in the regulations are $2,000,000 for contracts involving the sale or purchase of pharmaceutical goods and $1,000,000 for other types of contracts. These changes aim to maintain the relevance of the legislative framework in the face of economic changes since the original thresholds were established in 1980. The regulations have immediate effect upon their notification in the Commonwealth of Australia Gazette.
Key Provisions
The main operative sections of the Commonwealth Serum Laboratories Regulations (Amendment) include the addition of a new sub-paragraph 19(1)(b)(iiia) which allows for the Minister to determine that the functions of the Commonwealth Serum Laboratories Commission (the Commission) may include cooperation with foreign or international entities in research relating to pharmaceutical production. This provision broadens the scope of the Commission's activities to include international collaboration, aligning with the evolving landscape of pharmaceutical research and production. Additionally, the regulations amend paragraphs 20(2)(a) and 20(2)(b) to adjust the financial thresholds above which the Minister's approval is required for contracts related to the sale or purchase of pharmaceutical goods. Specifically, the new thresholds set by the regulations are $2,000,000 for contracts related to pharmaceutical goods and $1,000,000 for other contracts, reflecting the increased value of such contracts since the original thresholds were set in 1980.
The obligations and requirements imposed by the amended regulations on the Commission are primarily concerned with ensuring that any international cooperation in pharmaceutical research is conducted in a manner consistent with the Act. Furthermore, the Commission must obtain the Minister's approval for contracts exceeding the newly prescribed thresholds. These adjustments are intended to streamline operational efficiency while maintaining oversight over significant financial commitments. The regulations also detail the types of operations that may be undertaken under the auspices of the new sub-paragraph, providing clarity on what constitutes permissible cooperative activities with external entities. Additionally, the minor drafting changes aim to ensure the regulations are up-to-date and reflect current practices.
The amended regulations introduce specific consequences for non-compliance with the new financial thresholds. If the Commission enters into a contract exceeding the new limits without the Minister's approval, it may face civil or administrative penalties. While the regulations do not explicitly state the maximum penalties for such breaches, they align with the broader legislative framework in which penalties can range from fines to more severe administrative sanctions. The intention behind these provisions is to ensure that the Commission operates within the bounds of its mandate while allowing for flexibility in managing its growing scope of activities. The increased thresholds are designed to accommodate the rising value of contracts without unduly burdening the Commission with unnecessary ministerial oversight for routine operations.